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1 |  INTRODUCTION
Deprescribing is the planned process of reducing or stopping med-
ication, supervised by a healthcare professional (HCP), in order to 
improve patient outcomes.1 This approach has emerged in the past 
decade from evidence of the adverse effects of polypharmacy and 
inappropriate drug use.2 Polypharmacy and potential overtreat-
ment are major problems in people with type 2 diabetes.3 Such 
individuals often receive intensive treatment of glucose-, blood 
pressure-, and lipid-lowering medications to prevent complica-
tions. However, in older people, the benefits of intensive glucose 
and cardiovascular risk factor control are uncertain because of 
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Abstract
Background: Individualizing goals for people with type 2 diabetes may result in deinten-
sification of medication, but a comprehensive picture of deprescribing practices is lacking.
Aims: To conduct a scoping review in order to assess the rates, determinants and 
success of implementing deprescribing of glucose-, blood pressure- or lipid-lowering 
medications in people with diabetes.
Methods: A systematic search on MEDLINE and Embase between January 2007 and 
January 2019 was carried out for deprescribing studies among people with diabetes. 
Outcomes were rates of deprescribing related to participant characteristics, the deter-
minants and success of deprescribing, and its implementation. Critical appraisal was 
conducted using predefined tools.
Results: Fourteen studies were included; eight reported on rates, nine on determi-
nants and six on success and implementation. Bias was high for studies on success of 
deprescribing. Deprescribing rates ranged from 14% to 27% in older people with low 
HbA1c levels, and from 16% to 19% in older people with low systolic blood pressure. 
Rates were not much affected by age, gender, frailty or life expectancy. Rates were 
higher when a reminder system was used to identify people with hypoglycaemia, 
which led to less overtreatment and fewer hypoglycaemic events. Most healthcare 
professionals accepted the concept of deprescribing but differed on when to conduct 
it. Deprescribing glucose-lowering medications could be successfully conducted in 
62% to 75% of participants with small rises in HbA1c.
Conclusions: Deprescribing of glucose-lowering medications seems feasible and ac-
ceptable, but was not widely implemented in the covered period. Support systems 
may enhance deprescribing. More studies on deprescribing blood pressure- and lipid-
lowering medications in people with diabetes are needed.
This is an open access article under the terms of the Creat ive Commo ns Attri butio n-NonCo mmercial License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK
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increased risks of hypoglycaemia, hypotension and mortality.4,5 
Treatment guidelines have therefore shifted to a more personal-
ized approach, where treatment goals may depend on an indi-
vidual's characteristics and preferences.6 This may result in less 
intensive treatment in older and frail people with any type of dia-
betes.7–10 To date, there is limited evidence regarding the benefits 
and risks of deprescribing in people with diabetes.11–13
Potential overtreatment appears to be common among older 
people with diabetes, and deprescribing may be difficult to im-
plement in practice.12,14–16 Clinical guidelines for the treatment 
of diabetes and cardiovascular risk factors focus more on inten-
sification than on deintensification of medications.17 Guidelines 
often do not provide clear recommendations on when or how to 
deintensify medication.18 In 2017, a guideline on deprescribing 
anti-hyperglycaemic agents in older individuals was published, 
including an algorithm with recommendations on when and how 
to deprescribe.19 In 2018, a UK stakeholder initiative also pre-
sented more specific guidance on deintensification thresholds for 
glucose-lowering medication.20 In the same year, the American 
College of Physicians issued a guidance statement that clinicians 
should consider deprescribing in all people with type 2 diabetes 
who achieve HbA1c levels below 48 mmol/mol (6.5%).
7 Recently, 
several deprescribing networks and organizations around the 
world have started to support deprescribing in clinical practice.21
To develop programmes for enhancing deprescribing in 
people with type 2 diabetes, we need to know more about the 
process and implementation of deprescribing. The main aim 
of the present scoping review was to generate an overview 
of what is known about the deprescribing rates in relation to 
participant characteristics, and the determinants and success 
of deprescribing and of interventions to implement depre-
scribing of glucose-, blood pressure- and/or lipid-lowering 
medications in people with diabetes.
2 |  METHODS
2.1 | Design and reporting
We conducted a scoping review to obtain a broad view on the 
available information and evidence by including a wide range 
of study designs, outcomes and populations.22 The Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
extension for Scoping Reviews (PRISMA-ScR) guideline 
and checklist was used for the search process and to guide 
reporting (Appendix S1).23
2.2 | Information search and data sources
A search for relevant articles in the past decade was con-
ducted in Embase and MEDLINE for the period from 1 
January 2007 to 1 January 2019. A combination of search 
terms for deprescribing (e.g. ‘deprescribe’, ‘deintensify’, 
‘discontinue’, ‘withdrawal’) and diabetes mellitus (e.g. 
‘diabetes mellitus’, ‘impaired glucose tolerance’) were used 
(Appendix S2). There was no restriction in our initial search 
on type of medication. Reference lists from included articles 
were screened to identify additional articles. This ‘snowball-
ing’ approach was used because previous work showed that 
it is difficult to develop a sensitive search strategy for this 
topic.24
2.3 | Eligibility criteria
2.3.1 | Definition of deprescribing
There is no internationally accepted definition of 
deprescribing. Based on the review by Reeve et al.,1 
deprescribing was defined as the planned process of (1) 
dosage decrease, (2) stepping down, or (3) withdrawal 
of medication without dosage increase, switching to an 
equivalent agent, or stepping up or addition of another 
agent, where the goal is to reduce the risk of harm and 
improve outcomes within the context of an individual's 
goals and preferences. Deprescribing is thus a proac-
tive process of medication deintensification.
What's new?
• Potential overtreatment is common among older 
people with diabetes.
• Deprescribing has gained attention in the past dec-
ade but may be difficult to implement.
• Deprescribing was uncommon in potentially over-
treated people with diabetes up to 2017.
• Deprescribing rates were marginally influenced 
by comorbidity or frailty.
• Healthcare professionals accepted the concept of 
deprescribing in diabetes.
• Decision-support tools can increase deprescribing 
and decrease hypoglycaemia.
• Little is known about deprescribing of blood pres-
sure- or lipid-lowering medications in people with 
diabetes.
• Healthcare professionals need additional support 
and guidance to enhance deprescribing in people 
with diabetes.
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2.3.2 | Included studies
The present scoping review considered studies that evalu-
ated some aspect of the process of deprescribing of glu-
cose-, blood pressure- and/or lipid-lowering medications in 
people with type 2 diabetes. Studies related to people with 
type 2 diabetes as well as people with any type of diabetes 
were included as the majority will concern type 2 diabetes. 
Given the aim of the present study, studies in people with 
diabetes focusing on (1) inappropriate medication in gen-
eral, (2) improving adherence or (3) reacting to acute drug-
related problems were excluded. Additionally, studies on 
medication changes related to end-of-life in people with di-
abetes were excluded. Experimental studies, observational 
studies, surveys, as well as qualitative and mixed-method 
studies, were eligible for inclusion. Reviews, comments, 
study protocols, opinions and editorials were excluded. 
In the process of title and abstract screening, articles in 
languages other than English, Dutch, German and French 
were not reviewed.
2.3.3 | Main outcomes
Outcomes included: (1) rates of deprescribing in relation 
to participants’ characteristics (e.g. HbA1c or systolic 
blood presure, age, comorbidity); (2) determinants asso-
ciated with the process of deprescribing (e.g. barriers and 
enablers from the perspectives of individuals with diabe-
tes and healthcare professionals); (3) success of depre-
scribing; and (4) success of interventions to implement 
deprescribing in people with diabetes. Notably, the out-
comes retrieved for this review are not necessarily the pri-
mary outcomes as defined by the authors of the included 
studies.
2.4 | Selection of sources of evidence and 
data extraction
Two authors (M.P.O., K.P.K.) developed the search 
strategy, and independently screened titles and ab-
stracts. A third author (P.D.) checked all potentially 
relevant records. Additionally, P.D. checked a quarter 
of the excluded records, confirming that no potentially 
relevant records had been missed. Potentially eligible 
articles were retrieved as full texts and examined for 
final inclusion by two authors (M.P.O., P.D.). Cohen's 
kappa statistic was calculated to assess inter-rater agree-
ment between authors for the title-abstract screening 
and for the full-text screening. Disagreements were re-
solved by discussion between the authors (M.P.O., P.D., 
K.P.K.) to reach consensus. Two authors (M.P.O., P.D.) 
independently extracted the following information on a 
data extraction form: research questions according to the 
defined outcomes; study design; study period; country 
in which the study was conducted; participants; setting; 
methods and instruments used; determinants or interven-
tions; definition of outcomes; statistical analysis; and re-
sults (Appendix S3).
2.5 | Synthesis of results and 
critical appraisal
A narrative and descriptive synthesis of the results was 
conducted as the included studies were heterogeneous with 
regard to research questions, study design, analysis and out-
comes. Critical appraisal of the included studies was con-
ducted by assessing the risk of bias. This was done by two 
authors (M.P.O., P.D.) using the National Heart, Lung and 
Blood Institute [National Insitute of Health (NIH)] tool for 
observational cohort and cross-sectional studies, the NIH 
tool for before-and-after studies with no control group,25 and 
the domain-based risk-of-bias tool for cross-sectional sur-
vey studies.26 These tools were slightly modified to cover 
the following domains for all study designs where possible: 
selection of participants; exposure measurement; outcome 
measurement; incomplete data; analysis; and sample size. All 
assessments were categorized as low, uncertain or high risk 
of bias (Appendix S4).
3 |  RESULTS
Fourteen articles were included in this scoping review 
(Figure 1). Agreement between reviewers (M.P.O. and 
K.K.) for title/abstract screening was 98.7%, with a 
kappa value of 0.44, mainly driven by larger inclusion 
of potential papers by one of the reviewers. All poten-
tially relevant papers indicated by either one of the re-
viewers were screened by a third reviewer (P.D.). The 
agreement for the full-text screening was 97.7%, with a 
kappa value of 0.90.
3.1 | Study characteristics and bias
The majority of the studies were conducted in the USA (Table 
1).15,16,27–38 The study periods covered ranged from 2001 to 
2017. Study methodologies comprised retrospective cohort 
studies,15,16,27–31 prospective cohort or before-and-after stud-
ies,32–36 and surveys.37,38
The studies looking at participant characteristics associ-
ated with deprescribing rates had a low risk of bias (Figure 
2).15,27–29 The studies looking at participant characteristics 
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associated with successful deprescribing and those re-
porting on the success of deprescribing had a high risk of 
bias.33,34,36 Those studies also included very small sample 
sizes. Finally, the studies reporting on the success of inter-
ventions to enhance deprescribing had an uncertain to high 
risk of bias.30,32,35
3.2 | Deprescribing rates
Six studies reported on rates of deprescribing glucose-lowering 
medications,15,16,27–29,31 including two studies that also provided 
deprescribing rates of blood pressure-lowering medications.15,29 
No study reported deprescribing rates of lipid-lowering 
F I G U R E  1  PRISMA flow diagram of identified studies. (a) For example, studies focusing on efficacy/safety of medication, inappropriate 
medication in general, improving adherence, or reducing drug-related problems
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medication in people with diabetes. Three studies included 
only adults with diabetes 16,28,29, whereas the other studies in-
cluded only older people, aged ≥65 years,27 >70 years,15 and 
>85 years.31 Studies looked at different time windows for as-
sessing deprescribing rates, ranging from 120 to 180 days after 
the index HbA1c or systolic blood pressure measurement.
3.2.1 | Deprescribing glucose-lowering 
medications and participant characteristics
Deprescribing rates among eligible adults ranged from 21% 
to 45% for very low HbA1c levels <42 mmol/mol (<6.0%), 
and similar rates were seen for higher HbA1c levels (Figure 
3a).16,28,29 Among older people, the rates ranged from 20% to 
27% for HbA1c levels <42 mmol/mol (<6.0%), and from 14% 
to 21% for HbA1c levels between 42 and 48 mmol/mol (6.0–
6.5%; Figure 3b),15,27,31 whereas this was 6% for HbA1c levels 
>64 mmol/mol (>8.0%).31 There were some indications that 
deprescribing occurred more often in people with more co-
morbidities or lower life expectancy.27,33 The rates, however, 
differed by less than five percentage points for people with 
different levels of clinical complexity,16 age, gender or race,27 
frailty,28,29 or life expectancy15 (Appendix S3: Table A). The 
association between the HbA1c levels and deprescribing was 
not significantly modified by health status or lower life expec-
tancy.15,28,29 The three low-quality studies looking at partici-
pants’ characteristics associated with successful deprescribing 
showed no consistent results (Appendix S3: Table B).33,35,36
3.2.2 | Deprescribing blood pressure-
lowering medications and participant 
characteristics
The deprescribing rate among eligible adults ranged from 
40% for systolic blood pressure levels <120 mmHg to 34% 
for levels >140 mmHg (Appendix S3: Table A).29 Among 
older people with very low (<120  mmHg) to low (120–
129 mmHg) blood pressure levels, the rates were 19% and 
16%, whereas this rate was 15% for higher blood pressure 
levels.15 There was a weak association between life expec-
tancy and deprescribing.15 Rates differed by three to eight 
percentage points for people with different levels of frailty,29 
or life expectancy.15 The association between systolic blood 
pressure levels and deprescribing was not significantly mod-
ified by health status15,29 (Appendix S3: Table B).
3.3 | Barriers and enablers for deprescribing
No studies exploring barriers and enablers for deprescrib-
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individuals with diabetes were found. Two survey studies 
looked into the beliefs and perspectives of HCPs regarding 
deprescribing of glucose-lowering medications.37,38 The con-
cept of deprescribing for people with diabetes was well ac-
cepted, although HCPs had different opinions on the HbA1c 
threshold at which they would initiate conversations about 
deprescribing. Other patient-related factors that could lead to 
deprescribing according to most HCPs were medication side 
effects, limited life expectancy, or polypharmacy.38 Beliefs 
about treatment benefits and concerns about vulnerability for 
malpractice claims were barriers for deprescribing 37. The ma-
jority of HCPs believed that clinical decision-support tools and 
patient education materials would be helpful to support the 
process of deprescribing.37
F I G U R E  2  Risk-of-bias summary. (a) Vimalananda et al. and (b) Wright et al. had two outcomes related with the study objectives: (1) the 
rates after implementation of the deprescribing programme in the cohort and (2) the success of the implementation programme. (c) Masumoto et al. 
and (d) Abdelhafiz et al. had two outcomes related with the study objectives: (1) the determinants related to successful deprescribing in the cohort 
and (2) the success of deprescribing
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3.4 | Success of deprescribing
In a small study in 32 nursing home residents with an HbA1c level 
of 42 mmol/mol (6.0%) or lower, deprescribing was successful in 
24 of them.34 After successful withdrawal of oral glucose-lower-
ing medications or reduced insulin, a slight increase in HbA1c level 
from 33 to 40 mmol/mol (5.2 to 5.8%) was seen. In another study, 
withdrawal of all glucose-lowering medications was conducted 
in eight older participants with no significant change between 
baseline HbA1c of 44  mmol/mol (6.2%) and 1-year follow-up 
HbA1c of 48 mmol/mol (6.5%).
33 In a third study, including 16 
eligible adults with stable HbA1c levels below 53  mmol/mol 
(7.0%), successful discontinuation was possible in 10 participants 
(62%), showing no significant changes between baseline HbA1c 
of 44 mmol/mol and 12-week HbA1c of 44 mmol/mol (6.2%).
36
Hypoglycaemia occurrence reduced significantly in a group 
of older people who had a self-reported risk of hypoglycaemia 
after deprescribing of glucose-lowering medications (n = 395) 
compared to those with no change in treatment (n = 387).30
3.5 | Success of interventions to enhance 
deprescribing
Three studies evaluated the success of deprescribing imple-
mentation programmes (Appendix S3: Table C).30,32,35 A 
F I G U R E  3  (a) Deprescribing rates among adults according to their index HbA1c level. (b) Deprescribing rates among older people according 
to their index HbA1c level. HbA1c values are given in International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) units (mmol/
mol); conversion to Diabetes Control and Complications Trial (DCCT) units (%) is as follows: 38 mmol/mol = 5.6%, 39 mmol/mol = 5.7%, 
42 mmol/mol = 6%, 46 mmol/mol = 6.4%, 48 mmol/mol = 6.5%, 52 mmol/mol = 6.9%, 58 mmol/mol = 7.5%, 64 mmol/mol = 8%
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reminder system, linked to the electronic medical records, 
to stimulate deprescribing glucose-lowering medication in 
older people with HbA1c levels <53 mmol/mol (<7.0%) re-
sulted in a deprescribing rate of 26%.30 A similar reminder 
system that was combined with a shared decision-making 
programme resulted in a deprescribing rate of 37%.32 Those 
rates were higher among people with fear or symptoms of 
hypoglycaemia (51–57%), or with severe or frequent hypo-
glycaemia (62–95%).30,32 There was a significant absolute 
reduction in the percentage of potentially overtreated people 
by 22% after 18 months.32 There was a reduction in percent-
ages of people at high risk of hypoglycaemia with an HbA1c 
<53 mmol/mol (<7.0%) from 35.7% to 28.4%, and similar 
relative reductions for people with an HbA1c <48  mmol/
mol (<6.5%).30 Finally, a complete withdrawal of glucose-
lowering medications was attempted as part of a medication 
review during hospitalization among 70 older people with 
diabetes, resulting in 58 people (65%) with good glycaemic 
control who received no medication at discharge.35
4 |  DISCUSSION
Deprescribing rates for glucose- and blood pressure-lower-
ing medications in older people of at least 65 years of age 
with diabetes were rather low, ranging from 14% to 27% for 
deprescribing of glucose-lowering medication in older peo-
ple with HbA1c levels <48  mmol/mol (<6.5%), and from 
16% to 19% for deprescribing of blood pressure-lowering 
medication in older people with systolic blood pressure lev-
els <130 mmHg. Deprescribing was somewhat more likely 
in people with high comorbidity or lower life expectancy, 
even though the rates remained quite low in such individuals. 
HCPs accepted the concept of deprescribing in people with 
diabetes, but differed in opinion regarding when to conduct 
deprescribing. Deprescribing of glucose-lowering medica-
tions occurred more often when a clinical reminder system 
was applied to identify potentially overtreated older people. 
Such a reminder programme appeared to reduce overtreat-
ment and hypoglycaemic events. Deprescribing of glucose-
lowering medications seemed possible in people with stable 
or tight glycaemic control without large increases in HbA1c, 
but better-quality studies are needed to draw firm conclu-
sions. Little is known about deprescribing of blood pressure- 
and lipid-lowering medications in people with diabetes.
Proactive medication deintensification in older people with 
diabetes and low risk factor levels needs more attention, given 
the low deprescribing rates observed. In older people with high 
HbA1c levels of more than 64 mmol/mol (8.0%), the rate of de-
prescribing was 6%, indicating that minimal deintensification 
will occur also in people with poorly controlled diabetes. To our 
surprise, there was little variation in deprescribing rates accord-
ing to participant characteristics, such as age or comorbidity. 
There may be several explanations for the observed low rates 
of deprescribing in people with diabetes. During the studied pe-
riod, HCPs may have received little guidance on when and how 
to conduct deprescribing. Moreover, few of the recommenda-
tions to deintensify treatment are based on strong evidence.4,17 
Strong evidence usually relies on randomized clinical trials 
(RCTs), but this scoping review confirms findings from previ-
ous reviews that RCTs evaluating the benefits and harms of de-
prescribing are still lacking.11–13 Based on limited evidence, the 
conclusion remains that deprescribing of glucose-lowering med-
ications without substantial deterioration of glycaemic control 
seems feasible. Notably, marginal increases in HbA1c, such as 
from 33 to 40 mmol/mol (5.2% to 5.8%),34 could be considered 
a failure of sufficient deprescribing if an individual was still on 
glucose-lowering medication. No evidence was found regarding 
the benefits or harms of deprescribing blood pressure- or lip-
id-lowering medication in people with diabetes. Recently, it was 
concluded that, for older people with diabetes in general, there is 
insufficient evidence to make firm conclusions about any posi-
tive or negative effects of discontinuing blood pressure-lowering 
drugs.39
Eligibility criteria for deprescribing varied among the stud-
ies but usually included HbA1c or systolic blood pressure levels 
below a certain level and/or being at high risk of adverse events. 
There is still debate about the eligibility criteria for deprescrib-
ing.40 Successful deprescribing in terms of benefits and harms 
is likely to depend on these criteria. Several low-quality stud-
ies showed that successful deprescribing of glucose-lowering 
medications was possible in 62% to 75% of older people with 
low and/or stable HbA1c levels
33,34,36; however, those studies in-
volved people in nursing home or clinical settings. There is a 
great need for large high-quality studies in primary care settings 
assessing the success in terms of benefits and harms. People with 
a high risk of hypoglycaemia are more likely to benefit from de-
prescribing glucose-lowering drugs. The present review showed 
that supportive strategies for deprescribing in such people may 
reduce overtreatment and hypoglycaemic events.30,32
In general, the concept of deprescribing glucose-lowering 
medications was well accepted among HCPs, although they 
had different opinions on when and how to deprescribe.37,38 
Many would initiate deprescribing in people experiencing 
adverse effects, but there was less agreement on other cri-
teria, including the HbA1c level below which they would 
consider deprescribing.37,38 Both intrinsic factors, such as 
knowledge and attitudes, and extrinsic factors, such as the 
individual's condition and aspects of the healthcare system, 
may influence the HCPs’ decisions to deprescribe. This is in 
line with barriers and enablers that have been identified for 
deprescribing in general.41
No studies assessing the perspectives of people with dia-
betes on deprescribing were identified. This is surprising be-
cause it has been acknowledged that individuals’ beliefs and 
preferences are important when considering deprescribing 
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41,42. In general, people with diabetes seem to be willing to 
reduce their medication if their physician says it is possible 
and appropriate.42 It is not clear whether this also holds for 
specific medication used by people with diabetes. HCPs 
may experience uncertainty about the outcomes when depre-
scribing such medication, and worries about negative conse-
quences appear to inhibit deprescribing.37,43 Furthermore, no 
studies looking at impact of deprescribing on quality of life 
or patient-reported treatment satisfaction or in terms of cost 
reduction were found.
Additional efforts are needed to enhance deprescribing 
in people with type 2 diabetes. Clinical decision-support 
tools, as well as patient education materials, may be of help 
to support the implementation of deprescribing.30,32,37 A 
recent study showed that the use of evidence-based guide-
lines supported with algorithms for deprescribing proton 
pump inhibitors, benzodiazepine receptor agonists and an-
tipsychotic drug classes increased HCPs’ self-efficacy in 
implementing a plan to reduce or discontinue such medi-
cation.44 So far, most initiatives for people with diabetes 
have focused on deprescribing of glucose-lowering medi-
cation. More attention is needed for deprescribing of blood 
pressure- and lipid-lowering medication. Importantly, the 
focus should shift from conducting deprescribing mainly 
in people who experience side effects to a more proactive 
approach of reducing overtreatment, particularly in comor-
bid or frail people with diabetes. For this, alerting systems 
identifying such individuals can be of help.32 This requires 
further implementation of detecting frailty in primary 
care. Recently, a frailty assessment pathway was proposed 
which could be incorporated in the diabetes care systems.45 
Furthermore, setting individualized treatment targets re-
sulting in shared decisions about deprescribing requires 
education and involvement.30 Informed people with diabe-
tes and HCPs with sufficient communication skills are the 
basis of successful shared decision-making.
In addition, more evidence about the benefits and harms 
of deprescribing is needed. To measure the impact of depre-
scribing glucose-, blood pressure- or lipid-lowering medica-
tions, one should not only focus on control of the specific 
risk factor, such as HbA1c. One of the aims of deprescribing 
may be less stringent risk factor control, and thus an increase 
in the risk factor level. Core outcome sets have been devel-
oped for trials of medication reviews and improving appro-
priateness of polypharmacy in older people,46,47 which are 
also relevant for deprescribing. Meaningful patient outcomes 
for studying the success of deprescribing include sufficient 
disease control without adverse effects, better quality of life, 
and reduction of medication burden and regimen complexity. 
Finally, studies are needed to assess the cost-effectiveness of 
deprescribing interventions.
This scoping review used a broad search strategy, fo-
cusing on deprescribing of glucose-, blood pressure- or 
lipid-lowering medications in people with diabetes, includ-
ing studies on interventions to enhance deprescribing and 
studies on determinants associated with deprescribing and 
its implementation. Thus, studies that were not identified in 
previous reviews were included.11–13 All review steps were 
conducted by two people, and risk of bias was assessed.
Some limitations should be mentioned. First, our 
search ended in 2019 and included studies with data up 
to 2017. It is possible that rates of deprescribing have in-
creased in more recent years, although we observed no 
trends towards more deprescribing in older people with 
diabetes over time. A recent study in 23 participants aged 
≥75 years, who had an HbA1c ≤53 mmol/mol (≤7%) with 
documented hypoglycaemia and were treated with a sul-
fonylurea or with insulin showed that deintensification of 
treatment still did not occur in more than half the cases.48 
Second, the retrieved outcomes were not necessarily the 
primary outcomes as defined by the authors of the in-
cluded studies. In some cases, it was difficult to extract 
the numbers needed for the outcomes, because they were 
not clearly reported. Third, given the definition of depre-
scribing, studies where medication was just simplified or 
switched or discontinued because of contraindications 
were excluded. For this reason, the study by Aspinall 
et al.,49 which was included in previous reviews, was ex-
cluded because it evaluated discontinuation of glyburide 
in participants with renal impairment, advising that an al-
ternative agent, such as glipizide, be considered. Inclusion 
of this study would not have changed the conclusions. 
Also, we did not focus on stopping medication at the end 
of life, because other considerations, such as a general 
wish to continue only palliative medication, become rel-
evant at that stage. None of the articles included for full-
text screening, however, were excluded for this reason. A 
recent study observed that end-of-life status may increase 
the likelihood of deprescribing glucose-lowering medica-
tions in nursing homes.50 Finally, the quality of many of 
the included studies was poor. When interpreting the re-
sults, this was taken into account.
In conclusion, deprescribing rates in people with diabetes 
were low to moderate and only marginally influenced by par-
ticipants’ comorbidity or frailty. The concept of deprescrib-
ing glucose-lowering medication in people with diabetes is 
supported, although its implementation in practice appears to 
be challenging and primarily focused on people experiencing 
drug-related problems. Deprescribing to reduce drug burden 
or to prevent future adverse events in vulnerable people is 
not yet common practice. To develop and implement plans 
for deprescribing in a broader range of people with diabetes, 
clinical decision-support tools and education materials could 
be useful. Evidence on the benefits and risks of deprescrib-
ing is poor and further attention should be paid to the effects 
on patient-relevant outcomes and costs. More research is also 
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needed about deprescribing of blood pressure- and lipid-low-
ering medications in people with diabetes.
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